By Colin Kellaher

Agios Pharmaceuticals Inc. Monday said it filed for U.S. Food and Drug Administration approval of mitapivat for the treatment of adults with pyruvate kinase, or PK, deficiency.

The Cambridge, Mass., biopharmaceutical company said there are currently no approved therapies for PK deficiency, a rare genetic disorder characterized by the premature destruction of red blood cells.

Agios said it is on track to file for European Union approval of mitapivat in mid-2021.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

June 21, 2021 07:37 ET (11:37 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Agios Pharmaceuticals Charts.
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Agios Pharmaceuticals Charts.